Follistatin-344 vs GDF-11

The distinction that mattersFollistatin blocks myostatin and activins to increase muscle. GDF-11 is myostatin-like and may reduce it. They are sold adjacently but may act in opposite directions.

	Follistatin-344 Research Use Only	GDF-11 Research Use Only
Evidence rating	1/5 Minimal Evidence rating 1 out of 5: Minimal	1/5 Minimal Evidence rating 1 out of 5: Minimal
Regulatory status	Not approved. Follistatin gene therapy has been studied in muscular dystrophy trials; injectable recombinant follistatin has not been developed for human use.	Preclinical research protein. No human trials. Not approved. Its central claims are scientifically contested.
Category	Bone, Muscle & Other	Longevity & Mitochondrial
Drug class	Recombinant follistatin isoform — an activin and myostatin-binding glycoprotein	TGF-beta superfamily protein, closely homologous to myostatin (GDF-8)
Route	Subcutaneous (research); gene therapy in trials	Intraperitoneal or subcutaneous (research)
Half-life	Very short as a protein — minutes to hours	Short; circulates bound to latency proteins
Studied in	AAV-delivered follistatin gene therapy phase 1/2 trials in Becker muscular dystrophy and inclusion body myositis; extensive animal work. No trials of injectable recombinant follistatin.	Mouse parabiosis and supplementation studies with directly conflicting results across laboratories. No human interventional trials.
Who should avoid it	All non-trial human use Cancer history — activin signalling is involved in tumour suppression	All human use — the underlying science is unresolved and the direction of effect is disputed
Legal status	Not approved for human use.	Not approved for human use.

Benefits — Follistatin-344

Dramatic muscle growth in animal models
Follistatin overexpression produces substantial and sustained muscle hypertrophy in mice and non-human primates.
Gene therapy signals in muscular dystrophy
Small early-phase trials reported improved 6-minute walk distance and muscle histology.
Antifibrotic activity
Activin blockade reduces fibrosis in preclinical models of muscle and organ disease.

Benefits — GDF-11

Reported cardiac rejuvenation in mice
The original work described reversal of age-related cardiac hypertrophy in aged mice given GDF-11.
Reported neurogenesis and vascular effects
Follow-up work from the same group described improved cerebral vasculature and neurogenesis.
Genuine developmental role
GDF-11 is unambiguously important in embryonic axial patterning — that part is not disputed.

Risks & cons — Follistatin-344

Injectable form is unstudied in humans
The trial evidence is for gene therapy — a completely different intervention with different pharmacology.
Activin blockade affects multiple systems
Reproductive function, inflammatory regulation and tissue repair all depend on activin signalling.
Tendon-muscle mismatch injury
Muscle hypertrophy outpacing tendon adaptation is a documented injury mechanism in myostatin-inhibited animals.
Cardiac muscle effects unknown
Myostatin is expressed in cardiac tissue; consequences of chronic inhibition in the heart are not characterised.
Very poor bioavailability
Rapid clearance makes injected recombinant follistatin unlikely to achieve meaningful sustained effect regardless.

Risks & cons — GDF-11

Core findings contested by independent groups
Other laboratories reported that GDF-11 does not decline with age, and that supplementation inhibits rather than promotes muscle regeneration. This is an active scientific dispute, not settled science.
Assay cross-reactivity problem
Because GDF-11 and myostatin are so similar, several early measurements may have been detecting myostatin instead.
Muscle atrophy in some studies
Given the myostatin homology, GDF-11 may suppress muscle growth — the opposite of what the anti-aging framing implies.
Cachexia signals
High GDF-11 levels have been associated with frailty and cachexia in some human observational work.
No human data
No trials, no dosing, no safety characterisation.

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.